他喷他多速释剂用于缓解拇囊炎术后中重度急性疼痛有效性和安全性的Meta分析 点击下载
论文标题: 他喷他多速释剂用于缓解拇囊炎术后中重度急性疼痛有效性和安全性的Meta分析
英文标题:
中文摘要: 目的:系统评价他喷他多速释剂(Tap IR)用于缓解拇囊炎术后中重度急性疼痛的有效性与安全性,为临床合理用药提供循证参考。方法:计算机检索PubMed、Medline、Cochrane图书馆、中国知网、维普数据库、万方数据库、美国临床试验网数据库,收集Tap IR(试验组)对比羟考酮速释剂或安慰剂用于缓解拇囊炎术后中重度急性疼痛的随机对照试验(RCT)。筛选文献、提取资料并采用改良Jadad量表评价文献质量后,采用Rev Man 5.3软件进行 Meta 分析。结果:共纳入6项RCT,共计2 378例患者。Meta 分析结果显示,试验组患者48 h疼痛缓解总值(TOTPAR48)显著高于对照组 [MD=35.60,95%CI(27.31,43.88),P<0.000 01]。亚组分析结果显示,试验组中使用50 mg[MD=28.68,95%CI(18.18,39.17),P<0.00 001]、75 mg[MD=39.97,95%CI(34.21,45.73),P<0.00 001]、100 mg[MD=38.50,95%CI(1.46,75.54),P=0.04]患者的TOTPAR48显著高于对照组;试验组中使用75 mg患者的TOTPAR48显著高于使用50 mg者[MD=9.04,95%CI(4.31,13.77),P=0.000 2]。两组患者补救药物使用率(URM)比较差异无统计学意义[RR=1.23,95%CI(0.84,1.80),P=0.29];亚组分析结果显示,试验组中使用75 mg患者的URM显著低于使用50 mg者[RR=0.62,95%CI(0.41,0.94),P=0.02]。试验组患者48 h疼痛强度差总值(SPID48)显著低于对照组[MD=-18.96,95%CI(-37.28,-0.64),P=0.04];亚组分析结果显示,试验组中使用75 mg患者的SPID48显著高于使用50 mg者[MD=21.66,95%CI(8.93,34.39),P=0.000 9]。两组患者总体疼痛印象改变值(PGIC)比较差异无统计学意义[RR=0.95,95%CI(0.88,1.03),P=0.23];亚组分析结果显示,试验组中使用75 mg患者的PGIC显著高于使用50 mg者[RR=1.07,95%CI(1.01,1.13),P=0.02],显著低于使用100 mg者[RR=0.86,95%CI(0.77,0.97),P=0.01]。试验组患者恶心、呕吐、便秘、头晕、头痛发生率均显著低于对照组(P<0.05)。结论:Tap IR用于缓解拇囊炎术后中重度急性疼痛的疗效与安全性均较好,且75 mg可能为其最佳用药剂量。
英文摘要: OBJECTIVE: To systematically evaluate the efficacy and safety of Tapentadol immediate-release preparation (Tap IR) for relieving severe acute pain after brachiocephalic arteritis, and to provide evidence-based reference for rational drug use. METHODS: Retrieved from PubMed, Medline, Cochrane library, CNKI, VIP, Wanfang database and American clinical trial database, randomized controlled trials (RCTs) about Tap IR (trial group) versus Oxycodone immediate-release preparation or placebo for relieving severe acute pain after brachiocephalic arteritis were collected. After literature screening, data extraction and literature quality evaluation with modified Jadad scale, Meta-analysis was conducted by using RevMan 5.3 software. RESULTS: A total of 6 RCTs were included, involving 2 378 patients. Results of Meta-analysis showed that 48 h total pain relief value (TOTPAR48) of trial group was significantly higher than control group [MD=35.60,95%CI(27.31, 43.88), P<0.000 01]. Results of sub-group analysis showed that TOTPAR48 of trial group using Tap IR 50 mg [MD=28.68, 95%CI (18.18, 39.17),P<0.00 001], 75 mg [MD=39.97, 95%CI (34.21, 45.73), P<0.000 01] and 100 mg[MD=38.50, 95%CI(1.46, 75.54),P=0.04] were significantly higher than control group; TOTPAR48 of patients who received Tap IR 75 mg were significantly higher than patients who received Tap IR 50 mg [MD=9.04,95% CI(4.31, 13.77),P=0.000 2]. There was no statistical significance in the utilization rate of rescue medicine (URM) between 2 groups [RR=1.23,95% CI(0.84, 1.80),P=0.29]. Subgroup analysis showed that URM in patients who received Tap IR 75 mg was significantly lower than those receiving Tap IR 50 mg [RR=0.62,95%CI(0.41, 0.94),P=0.02]. The total difference of 48 h pain intensity (SPID48) in trial group was significantly lower than control group [MD=-18.96,95%CI(-37.28,-0.64),P=0.04]. Subgroup analysis showed that SPID48 in patients who received Tap IR 75 mg was significantly higher than those receiving Tap IR 50 mg [MD=21.66,95%CI(8.93, 34.39),P=0.000 9]. There was no statistical significance in the total change of pain impression (PGIC) between 2 groups [RR=0.95,95%CI(0.88, 1.03),P=0.23]. Subgroup analysis showed that PGIC in patients who received Tap IR 75 mg was significantly higher than those receiving Tap IR 50 mg [RR=1.07,95%CI(1.01, 1.13),P=0.02] but significantly lower than those receiving Tap IR 100 mg [RR=0.86,95%CI(0.77, 0.97),P=0.01]. The incidence of nausea, vomiting, constipation, dizziness and headache in trial group were significantly lower than control group (P<0.05). CONCLUSIONS: Tap IR shows good therapeutic efficacy and safety for severe acute pain after brachiocephalic arteritis, and the efficacy of Tap IR might be better when the dose of Tap IR is 75 mg.
期刊: 2019年第30卷第8期
作者: 何淼泉,王继生,肖京平,王昀子,刘阳,郭濠宁
英文作者: HE Miaoquan,WANG Jisheng,XIAO Jingping,WANG Yunzi,LIU Yang,GUO Haoning
关键字: 他喷他多速释剂;羟考酮速释剂;拇囊炎;术后;中重度急性疼痛;疗效;安全性;Meta 分析
KEYWORDS: Tapentadol immediate-release preparation; Oxycodone immediate-release preparation; Brachiocephalic arteritis; Post-operative; Moderate and severe acute pain; Therapeutic efficacy; Safety; Meta-analysis
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!